Stockscreener 앱 받기
1.10
0.00%
0.00
시간 외 거래:
1.12
0.02
+1.82%
전일 마감가:
$1.10
열려 있는:
$1.08
하루 거래량:
2.67M
Relative Volume:
1.14
시가총액:
$830.60M
수익:
$581.12M
순이익/손실:
$-212.92M
주가수익비율:
-4.0175
EPS:
-0.2738
순현금흐름:
$-174.22M
1주 성능:
-3.51%
1개월 성능:
-6.78%
6개월 성능:
-14.06%
1년 성능:
-17.29%
1일 변동 폭
$1.075
$1.125
1주일 범위
$1.075
$1.14
52주 변동 폭
$0.9769
$1.60
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.10 | 830.60M | 581.12M | -212.92M | -174.22M | -0.2738 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | JP Morgan | Neutral |
| 2025-10-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-25 | 개시 | JP Morgan | Neutral |
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies - Yahoo Finance
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan
Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan
OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
Order lab tests online or at home: BioReference opens new platform - Stock Titan
OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada
Barrington Research downgrades OPKO Health (OPK) - MSN
OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat
OPKO Health Q1 Earnings Call Highlights - MarketBeat
OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip By Investing.com - Investing.com South Africa
Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip - Investing.com Nigeria
Earnings Flash (OPK) OPKO Health Posts Q1 Loss of $0.07 per Share, vs. FactSet Est of $0.07 Loss - marketscreener.com
OPKO Health Inc (NASDAQ:OPK) Misses Q1 Revenue Estimates, Shares Slide After Hours - ChartMill
OPKO Health: Q1 Earnings Snapshot - Barchart.com
OPKO Health (NASDAQ:OPK) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings Flash (OPK) OPKO Health, Inc. Reports Q1 Revenue $124.2M, vs. FactSet Est of $130.5M - marketscreener.com
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results - The Manila Times
(OPK) OPKO Health, Inc. Expects Q2 Revenue Range $127.0M$132.0M - marketscreener.com
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opko Health Inc 주식 (OPK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 21 '25 |
Buy |
1.33 |
580,000 |
768,807 |
216,706,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 20 '25 |
Buy |
1.33 |
580,000 |
771,328 |
216,126,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 19 '25 |
Buy |
1.31 |
580,000 |
759,115 |
215,546,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Nov 18 '25 |
Buy |
1.27 |
533,300 |
678,906 |
214,966,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Oct 31 '25 |
Buy |
1.42 |
150,000 |
213,435 |
214,386,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Aug 08 '25 |
Buy |
1.32 |
675,000 |
891,000 |
214,676,448 |
0.71%
자본화:
|
볼륨(24시간):